The stock of German drug-discovery and development company Evotech SE jumped 4% early Monday, after Halozyme Therapeutics Inc ...

Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...

ADRs quickly plunged 9% in premarket trading amid a report that the company is preparing to fight back against Halozye ...

Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, ...

Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in ...

圣地亚哥 - Halozyme Therapeutics, Inc. (NASDAQ: HALO) 今日宣布计划以每股11.00欧元的价格收购Evotec SE (NASDAQ: EVO)，这笔全现金交易总价值20亿欧元。此次交易旨在打造一家全球领先的制药服务公司，显著扩大和多元化Halozyme的业务范围和财务前景。 这项拟议收购预计将利用Halozyme现有技术和Evotec的平台，创建一个收 ...

Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .

周五，Piper Sandler维持对Halozyme Therapeutics (NASDAQ: HALO)的中性评级，目标价为52.00美元。该公司的分析是在Halozyme确认有意以每股11美元收购Evotec之后进行的，这笔交易将使Evotec的完全稀释后股权价值约为20亿欧元。 以ENHANZE药物输送技术闻名的Halozyme认为，收购Evotec是一项战略举措，可以扩大其为药物开发商 ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...

Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley. “We feel ...

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Halozyme (HALO – Research Report), retaining the price target of $62.00. Mohit Bansal’s rating is based on a mix of strategic ...